Monte Rosa Therapeutics Inc [NASDAQ: GLUE] traded at a high on 2025-09-15, posting a 44.07 gain after which it closed the day’ session at $6.93.
The results of the trading session contributed to over 31553435 shares changing hands. Over the past one week, the price volatility of Monte Rosa Therapeutics Inc stands at 6.82% while the volatility over the past one month is 5.53%.
The market cap for GLUE stock reached $428.00 million, with 61.72 million shares outstanding and 46.18 million shares in the current float. Compared to the average trading volume of 407.96K shares, GLUE reached a trading volume of 31553435 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Monte Rosa Therapeutics Inc [GLUE]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GLUE shares is $16.71 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GLUE stock is a recommendation set at 1.22. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wells Fargo have made an estimate for Monte Rosa Therapeutics Inc shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on December 19, 2024. While these analysts kept the previous recommendation, Wedbush raised their target price to Outperform. The new note on the price target was released on February 15, 2024, representing the official price target for Monte Rosa Therapeutics Inc stock. Previously, the target price had yet another raise to $18, while Wells Fargo analysts kept a Overweight rating on GLUE stock.
The Price to Book ratio for the last quarter was 1.60, with the Price to Cash per share for the same quarter was set at 4.71. Price to Free Cash Flow for GLUE in the course of the last twelve months was 17.95 with Quick ratio for the last quarter at 7.16.
How has GLUE stock performed recently?
Monte Rosa Therapeutics Inc [GLUE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 44.37. With this latest performance, GLUE shares gained by 59.31% in over the last four-week period, additionally plugging by 10.53% over the last 6 months – not to mention a drop of -0.14% in the past year of trading.
Monte Rosa Therapeutics Inc [GLUE]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Monte Rosa Therapeutics Inc [GLUE] shares currently have an operating margin of 8.40% and a Gross Margin at 95.32%. Monte Rosa Therapeutics Inc’s Net Margin is presently recorded at 13.58%.
Monte Rosa Therapeutics Inc (GLUE) Capital Structure & Debt Analysis
According to recent financial data for Monte Rosa Therapeutics Inc. ( GLUE), the Return on Equity (ROE) stands at 9.81%, suggesting modest shareholder returns. The Return on Assets (ROA) is 6.87%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Monte Rosa Therapeutics Inc’s Return on Invested Capital (ROIC) is 7.92%, showcasing its effectiveness in deploying capital for earnings.
Monte Rosa Therapeutics Inc (GLUE) Efficiency & Liquidity Metrics
Based on Monte Rosa Therapeutics Inc’s (GLUE) latest financial statements, the Debt-to-Equity Ratio is 0.15%, indicating its reliance on debt financing relative to shareholder equity.
Monte Rosa Therapeutics Inc (GLUE) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Monte Rosa Therapeutics Inc. (GLUE) effectively leverages its workforce, generating an average of $180373.13 per employee. The company’s liquidity position is robust, with a Current Ratio of 7.16% and a Quick Ratio of 7.16%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Monte Rosa Therapeutics Inc [GLUE]
With the latest financial reports released by the company, Monte Rosa Therapeutics Inc posted -0.29/share EPS, while the average EPS was predicted by analysts to be reported at -0.47/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.18. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GLUE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Monte Rosa Therapeutics Inc go to -8.99%.
Insider trade positions for Monte Rosa Therapeutics Inc [GLUE]
There are presently around $100.42%, or 101.16%% of GLUE stock, in the hands of institutional investors. The top three institutional holders of GLUE stocks are: NEA MANAGEMENT COMPANY, LLC with ownership of 7.69 million shares, which is approximately 10.7986%. PRICE T ROWE ASSOCIATES INC /MD/, holding 5.98 million shares of the stock with an approximate value of $$22.36 million in GLUE stocks shares; and PRICE T ROWE ASSOCIATES INC /MD/, currently with $$19.06 million in GLUE stock with ownership which is approximately 7.1524%.
